Erlotinib: a new therapeutic approach for non-small cell lung cancer

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.8, 2003-08, pp. : 1395-1401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib in non-small cell lung cancer: a review

By Blackhall Fiona H Rehman Shazza Thatcher Nicholas

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 995-1002

Informa Healthcare

Access to resources Recommend Favorite

Reviewing the safety of erlotinib in non-small cell lung cancer

By Reck Martin Mok Tony Wolf Jürgen Heigener David Wu Yi-long

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 147-157

Informa Healthcare

Access to resources Recommend Favorite

Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 85-94

Bentham Science Publishers

Access to resources Recommend Favorite

Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer: Update

Medicinal Chemistry Reviews - Online, Vol. 1, Iss. 3, 2004-01 ,pp. : 253-256

Bentham Science Publishers

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite